Market Overview

Vetr Crowd Bearish On GW Pharma, But Upgrades To 3-Star Rating

Vetr Crowd Bearish On GW Pharma, But Upgrades To 3-Star Rating
Related GWPH
GW Pharma Continues To Move On Takeover Speculation
GW Pharma Set To Fly High: Goldman Sachs Starts Coverage At Buy, Sees 42% Upside
New Bullish Factors Emerge For GW Pharma Medical Marijuana Play (Seeking Alpha)

GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) has risen to $91.57 since its previous Vetr rating of 2.5 stars was issued two days ago. On Friday, the Vetr community upgraded their rating to three stars.

The British pharmaceutical company rallied on Tuesday on the release of positive data from their drug Epidiolex.

Related Link: GW Pharmaceuticals Surrenders Big Pre-Market Gains

Overall though, sentiment on Vetr is bearish. Less than 2 percent of Vetr users are holding it in their watch-lists, and 57 percent of the crowd's ratings are bearish. The Vetr crowd sees a price target of $89.66, compared to analyst projections $131.25.

See how Vetr's crowdsourced ratings can help you beat the market.

At time of writing, GW Pharma was up 1.64 percent at $93.07.

Latest Ratings for GWPH

Oct 2016Leerink SwannAssumesOutperform
Sep 2016Morgan StanleyMaintainsOverweight
Sep 2016Cantor FitzgeraldMaintainsBuy

View More Analyst Ratings for GWPH
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Downgrades Health Care Crowdsourcing Analyst Ratings Trading Ideas General


Related Articles (GWPH)

View Comments and Join the Discussion!